Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 33 от 154

Набира участници Фаза 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-Cell Lymphoma, Non-Hodgkin (NHL) Lymphoma, Large B-Cell, Diffuse (DLBCL) Chronic Lymphocytic Leukemia (CLL)

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).

Начало: 10.03.2025 Край: 01.03.2029 Възраст: от 18 г. Лечение

Australia, United States Umoja Biopharma NCT06528301

Набира участници Фаза 1

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Начало: 10.03.2025 Край: 16.04.2029 Възраст: от 18 г. Лечение

Australia, South Africa, United States AstraZeneca NCT06879041

Набира участници Фаза 3

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.

Начало: 10.03.2025 Край: 26.01.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +9 Takeda NCT06671496

Набира участници Фаза 2

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

Melanoma Metastatic

The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body. Radiotherapy uses x-rays to target and kill melanoma cells and immunotherapy works by activating the body's own immune system to seek out and ﬁght melanoma cells. Both of these treatments are commonly given to patients with advanced melanoma and other cancers. Both treatments are usually given separately but can also be given together. The aim of this research is to find out if giving radiotherapy and immunotherapy together is better than giving immunotherapy alone. The type of radiotherapy to be used in this project is known as 'stereotactic' body radiotherapy or SBRT (also known as stereotactic body ablative radiotherapy, SABR). SBRT targets the radiation very precisely at the metastatic deposits in the body. This method protects the healthy areas near the melanoma. SBRT works by delivering a high dose of radiation precisely to the areas of melanoma which causes the melanoma cells to break apart and eventually die. SBRT is given in 'fractions' which means the high dose is given in small measures over several days, depending on the number and size of metastases.

Начало: 06.03.2025 Край: 01.04.2033 Възраст: от 18 г. Лечение

Australia, Canada Melanoma Institute Australia NCT06767306

Набира участници Фаза 2

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkins Lymphoma

This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.

Начало: 05.03.2025 Край: 30.03.2029 Възраст: от 18 г. Лечение

Australia, Canada, France +4 Hoffmann-La Roche NCT06806033

Набира участници Фаза 1/2

A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors

Tumours, Gynecological

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable GSK5733584 is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.

Начало: 04.03.2025 Край: 05.04.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +16 GlaxoSmithKline NCT06796907

Набира участници Фаза 3

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Chronic Kidney Disease and Hypertension

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Начало: 03.03.2025 Край: 18.12.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +38 AstraZeneca NCT06742723

Набира участници Фаза 3

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Начало: 03.03.2025 Край: 28.01.2028 Възраст: от 18 г. Лечение

Belgium, Bulgaria, Chile +16 Takeda NCT06671483

Набира участници Фаза 2

Study of Olutasidenib and Temozolomide in HGG

High Grade Glioma Astrocytoma Astrocytoma, Grade III Astrocytoma, Grade IV +15

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

Начало: 01.03.2025 Край: 01.06.2035 Възраст: 12–39 г. Лечение

Australia, Canada, Germany +3 Rigel Pharmaceuticals NCT06161974

Набира участници

Spinal Cord Injury Neurorecovery Collaboration

Spinal Cord Injuries

SCINC is an adaptive design Master protocol that seeks to determine if there is "sufficient promise" of beneficial effect of treatment combinations to enhance motor recovery in pre-specified strata of people with a spinal cord injury.

Начало: 01.03.2025 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia University of Melbourne NCT06871254

Набира участници Фаза 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

HER2-positive Gastric Cancer Gastroesophageal Junction Adenocarcinoma

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Начало: 01.03.2025 Край: 09.12.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 AstraZeneca NCT06764875

Набира участници Фаза 1

A Phase 1 Study of S-1117

Healthy Volunteer

This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.

Начало: 01.03.2025 Край: 01.03.2026 Възраст: 18–65 г. Лечение

Australia Seismic Therapeutic AU Pty Ltd NCT06828393

Набира участници

Exploring the Health Benefits of Sauna Bathing

Blood Pressure

Cardiovascular disease (CVD) is the leading cause of mortality in Aotearoa New Zealand, with hypertension being a major risk factor that remains difficult to manage with medication. Finnish sauna bathing (FSB), a widely practiced form of heat therapy, has been linked to lower risks of CVD, stroke, and overall mortality. Traditionally, FSB is combined with cold water immersion (CWI), but the combined effects of these therapies remain under explored. While sauna research often focuses on physiological aspects, this study aims to take a holistic approach to understanding its impact on cardiovascular health.

Начало: 01.03.2025 Край: 01.07.2025 Възраст: 18–70 г. Превенция

New Zealand The Centre for Health NCT06875466

Набира участници Фаза 3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Hidradenitis Suppurativa (HS)

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Начало: 28.02.2025 Край: 28.02.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +16 Incyte Corporation NCT06855498

Набира участници Фаза 3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).

Начало: 27.02.2025 Край: 28.12.2027 Възраст: от 18 г. Лечение

Australia, Bulgaria, China +13 Takeda NCT06722235

Набира участници Фаза 3

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

Intracerebral Hemorrhage Spontaneous Intracerebral Hemorrhage Supratentorial Intracerebral Haemorrhage Acute Intracerebral Haemorrhage +1

This is a domain within the ACT-GLOBAL platform trial to compare the effectiveness of early and appropriate pharmacological interventions in acute intracerebral hemorrhage (ICH) to control secondary brain injury. Up to 2000 patients with presumed spontaneous supratentorial intracerebral hemorrhage (ICH) will be followed for 6 months (or death, if prior to 6 months). Adaptive interim analyses will be used, with statistical triggers to determine if any of the interventions are superior to control. The end of the trial is defined as the date that all participants have completed their 6-month assessment. A large amount of preclinical data indicates that the outcome from ICH is linked to the detrimental effects of breakdown substances from brain bleeds. However, there remains a lack of compelling evidence supporting the effectiveness of any pharmacological intervention that can mitigate the secondary cerebral injury. The INTERACT domain aims to assess the effectiveness of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, to standard of care alone, on improving functional outcome in patients with spontaneous supratentorial ICH. Those patients who meet eligibility criteria will be randomized to receive one of four interventions: 1. No deferoxamine mesylate and no colchicine (labeled as control) 2. Deferoxamine mesylate only: deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days. 3. Colchicine only: 0.5mg of oral colchicine daily for 30 consecutive days. 4. Both deferoxamine mesylate and colchicine: deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days.

Начало: 27.02.2025 Край: 01.01.2028 Възраст: 18–80 г. Лечение

Australia, China The George Institute NCT06763055

Набира участници Фаза 1

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Atopic Dermatitis

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Начало: 27.02.2025 Край: 06.02.2027 Възраст: 18–65 г. Лечение

Australia, New Zealand, United States Bambusa Therapeutics NCT06808477

Набира участници Фаза 2/3

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Prostate Cancer

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Начало: 27.02.2025 Край: 19.07.2033 Възраст: 18–100 г. Лечение

Australia, Brazil, China +8 Novartis Pharmaceuticals NCT06780670

Набира участници Фаза 3

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Gastric Cancer Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS \

Начало: 27.02.2025 Край: 01.02.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 Daiichi Sankyo NCT06731478

Набира участници Фаза 1

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.

Начало: 25.02.2025 Край: 01.08.2027 Възраст: от 18 г. Лечение

Australia, United States Vividion Therapeutics, Inc. NCT06804824

1 … 31 32 33 34 35 … 154